DDI-DrugBank.d647.s0 >> ZANOSAR may demonstrate additive toxicity when used in combination with other cytotoxic drugs. >> 0-6
DDI-DrugBank.d647.s1 >> Streptozocin has been reported to prolong the elimination half-life of doxorubicin and may lead to severe bone marrow suppression; >> 0-11,71-81
DDI-DrugBank.d647.s2 >> a reduction of the doxorubicin dosage should be considered in patients receiving ZANOSAR concurrently. >> 19-29,81-87
DDI-DrugBank.d647.s3 >> The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity. >> 22-33,39-47,100-111
